Solid Biosciences Faces Stock Slump as DMD Therapy Hurdles WorsenSolid Biosciences struggles: $6.28 stock, negative P/E, and a stalled Duchenne‑muscular‑dystrophy pipeline—will the biotech’s promise revive investor confidence?SOLID BIOSCIENCES INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 04/11/2026, 23:01 3 minutes to read